Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Multiple Sclerosis

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 75 articles:
HTML format



Single Articles


    December 2022
  1. CURRAN C, Vaitaitis G, Waid D, Volmer T, et al
    Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS).
    J Neuroimmunol. 2022;374:578008.
    PubMed     Abstract available


    November 2022
  2. SHU Y, Ma X, Chen C, Wang Y, et al
    Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms.
    J Neuroimmunol. 2022;372:577937.
    PubMed     Abstract available


    October 2022
  3. LI X, Chu Y, Ma R, Dou M, et al
    Ferroptosis as a mechanism of oligodendrocyte loss and demyelination in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;373:577995.
    PubMed     Abstract available


  4. CUTELLE C, Balducci C, Cereda D, Fusco ML, et al
    K index utility as diagnostic and prognostic biomarker in the assessment of patients with suspected Multiple Sclerosis.
    J Neuroimmunol. 2022;373:577992.
    PubMed     Abstract available


  5. DE SOUZA TIEPPO EM, da Silva TFF, de Araujo RS, Silva GD, et al
    Primary angiitis of the central nervous system as a mimic of multiple sclerosis: A case report.
    J Neuroimmunol. 2022;373:577991.
    PubMed     Abstract available


  6. FEIZI P, Sharma K, Pasham SR, Nirwan L, et al
    Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review.
    J Neuroimmunol. 2022;371:577939.
    PubMed     Abstract available


    September 2022
  7. FARAJI J, Gustafson C, Bettenson D, Negoro H, et al
    Bladder dysfunction in experimental autoimmune encephalomyelitis reflects clinical severity: A pilot study.
    J Neuroimmunol. 2022;372:577973.
    PubMed     Abstract available


  8. MAGALASHVILI D, Mandel M, Dreyer-Alster S, Didikin M, et al
    Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4.
    J Neuroimmunol. 2022;372:577966.
    PubMed     Abstract available


    July 2022
  9. ALOISI F, Cross AH
    MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis.
    J Neuroimmunol. 2022;371:577935.
    PubMed     Abstract available


  10. FUCHS L, Mausner-Fainberg K, Luban A, Asseyer SE, et al
    CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis.
    J Neuroimmunol. 2022;371:577936.
    PubMed     Abstract available


  11. DAS NEVES SP, Serre-Miranda C, Sousa JC, Costa PS, et al
    Lipocalin-2 does not influence EAE clinical score but it increases inflammation in central nervous system.
    J Neuroimmunol. 2022;368:577872.
    PubMed     Abstract available


  12. VAN DER WEELE L, Pollastro S, van Schaik BDC, van Kampen AHC, et al
    Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif) using B cell receptor repertoire analysis.
    J Neuroimmunol. 2022;370:577932.
    PubMed     Abstract available


  13. KASHEKE GDS, Holman SP, Robertson GS
    Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;370:577926.
    PubMed     Abstract available


    June 2022
  14. CHAN F, Riminton DS, Ramanathan S, Reddel SW, et al
    Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to "overlap" cases.
    J Neuroimmunol. 2022;369:577904.
    PubMed     Abstract available


    April 2022
  15. KYLLESBECH C, Trier N, Slibinskas R, Ciplys E, et al
    Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis.
    J Neuroimmunol. 2022;367:577868.
    PubMed     Abstract available


    March 2022
  16. TOTTENHAM I, Koch M, Camara-Lemarroy C
    Serum HGF and APN2 are associated with disability worsening in SPMS.
    J Neuroimmunol. 2022;364:577803.
    PubMed     Abstract available


  17. SALARI AA, Jand Y, Ghazi-Khansari M
    Antibiotic treatment during pregnancy and lactation in dams exacerbates clinical symptoms and inflammatory responses in offspring with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;366:577840.
    PubMed     Abstract available


    January 2022
  18. KALININ S, Boullerne AI, Feinstein DL
    Serum levels of lipocalin-2 are elevated at early times in African American relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2022;364:577810.
    PubMed     Abstract available


  19. YE F, Dai Y, Wang T, Liang J, et al
    Trans-omics analyses revealed key epigenetic genes associated with overall survival in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2022;364:577809.
    PubMed     Abstract available


  20. BRORSON IS, Eriksson AM, Hogestol E, Leikfoss IS, et al
    Global DNA methylation changes in treated and untreated MS patients measured over time.
    J Neuroimmunol. 2022;364:577808.
    PubMed     Abstract available


    December 2021
  21. TALBOT J, Hojsgaard Chow H, Holm Hansen R, von Essen MR, et al
    Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS.
    J Neuroimmunol. 2021;361:577756.
    PubMed     Abstract available


  22. KESHVARI MK, van Someren F, Sheikh S, Galea I, et al
    Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns.
    J Neuroimmunol. 2021;361:577729.
    PubMed     Abstract available


  23. ADAMEC I, Rogic D, Penz MG, Braun C, et al
    Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.
    J Neuroimmunol. 2021;362:577788.
    PubMed     Abstract available


  24. TOLJAN K, Amin M, Kunchok A, Ontaneda D, et al
    New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure.
    J Neuroimmunol. 2021;362:577785.
    PubMed     Abstract available


    November 2021
  25. CARAVAGNA C
    Comments on "Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine" by , J Neuroimmunol.
    J Neuroimmunol. 2021;362:577780.
    PubMed    


  26. HASSANSHAHI G, Noroozi Karimabad M, Jebali A
    The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I.
    J Neuroimmunol. 2021;362:577768.
    PubMed     Abstract available


  27. FREEDMAN MS, Wojcik J, Holmberg KH, Fluck M, et al
    Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION.
    J Neuroimmunol. 2021;360:577715.
    PubMed     Abstract available


  28. PACHE F, Ringelstein M, Aktas O, Kleiter I, et al
    C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
    J Neuroimmunol. 2021;360:577699.
    PubMed     Abstract available


  29. MASCIA E, Clarelli F, Zauli A, Guaschino C, et al
    Burden of rare coding variants in an Italian cohort of familial multiple sclerosis.
    J Neuroimmunol. 2021;362:577760.
    PubMed     Abstract available


    October 2021
  30. VAKRAKOU AG, Tzanetakos D, Evangelopoulos ME, Fragoulis GE, et al
    IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;361:577759.
    PubMed     Abstract available


  31. FUJIMORI J, Miyazawa K, Nakashima I
    Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neuroimmunol. 2021;361:577755.
    PubMed     Abstract available


  32. ACHIRON A, Mandel M, Dreyer-Alster S, Harari G, et al
    Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.
    J Neuroimmunol. 2021;361:577746.
    PubMed     Abstract available


    September 2021
  33. SRIWASTAVA S, Kataria S, Srivastava S, Kazemlou S, et al
    Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2021;360:577721.
    PubMed     Abstract available


    August 2021
  34. HAYASHI F, Isobe N, Cossu D, Yokoyama K, et al
    Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis.
    J Neuroimmunol. 2021;360:577701.
    PubMed     Abstract available


  35. FARSHBAFNADI M, Agah E, Rezaei N
    The second brain: The connection between gut microbiota composition and multiple sclerosis.
    J Neuroimmunol. 2021;360:577700.
    PubMed     Abstract available


  36. RIBES GARCIA S, Casanova Estruch B, Gomez Pajares F, Juan Blanco MA, et al
    Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.
    J Neuroimmunol. 2021;359:577698.
    PubMed     Abstract available


  37. HABEK M, Jakob Brecl G, Basic Kes V, Rogic D, et al
    Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    J Neuroimmunol. 2021;359:577696.
    PubMed     Abstract available


  38. HAHAM N, Vaknin-Dembinsky A
    COVID-19 in Cladribine-treated patient with multiple sclerosis.
    J Neuroimmunol. 2021;359:577690.
    PubMed     Abstract available


    July 2021
  39. KRAUS EE, Kakuk-Atkins L, Farinas MF, Jeffers M, et al
    Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.
    J Neuroimmunol. 2021;359:577675.
    PubMed     Abstract available


  40. LOVETT-RACKE AE, Yang Y, Liu Y, Gormley M, et al
    B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
    J Neuroimmunol. 2021;359:577676.
    PubMed     Abstract available


  41. NISHRI Y, Fainstein N, Goldfarb S, Hampton D, et al
    Modeling compartmentalized chronic immune-mediated demyelinating CNS disease in the Biozzi ABH mouse.
    J Neuroimmunol. 2021;356:577582.
    PubMed     Abstract available


  42. MIMPEN M, Damoiseaux J, van Doorn W, Rolf L, et al
    Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;358:577664.
    PubMed     Abstract available


  43. IVANOVA M, Voronkova A, Sukhorukov V, Zakharova M, et al
    Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis.
    J Neuroimmunol. 2021;358:577650.
    PubMed     Abstract available


    June 2021
  44. MIRZAEI R, Zamani F, Hajibaba M, Rasouli-Saravani A, et al
    The pathogenic, therapeutic and diagnostic role of exosomal microrna in the autoimmune diseases.
    J Neuroimmunol. 2021;358:577640.
    PubMed     Abstract available


  45. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
    Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
    J Neuroimmunol. 2021;358:577636.
    PubMed     Abstract available


  46. REYES S, Cunningham AL, Kalincik T, Havrdova EK, et al
    Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
    J Neuroimmunol. 2021;357:577627.
    PubMed     Abstract available


  47. NIINO M, Fukazawa T, Miyazaki Y, Ura S, et al
    Seasonal fluctuations in serum levels of vitamin D in Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2021;357:577624.
    PubMed     Abstract available


    May 2021
  48. SVIRIDOVA A, Rogovskii V, Kudrin V, Pashenkov M, et al
    The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis.
    J Neuroimmunol. 2021;356:577608.
    PubMed     Abstract available


  49. SOLTANMORADI S, Tavakolpour V, Moghadasi AN, Kouhkan F, et al
    Expression analysis of NF-kappaB-associated long noncoding RNAs in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577602.
    PubMed     Abstract available


  50. KELLY H, Sokola B, Abboud H
    Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577599.
    PubMed     Abstract available


    April 2021
  51. YOKOTE H
    Author's response in reply to "Question about data: Importance of serum amyloid A level in patients with multiple sclerosis".
    J Neuroimmunol. 2021;356:577589.
    PubMed    


  52. GARCIA-MANTEIGA JM, Clarelli F, Bonfiglio S, Mascia E, et al
    Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.
    J Neuroimmunol. 2021;356:577600.
    PubMed     Abstract available


  53. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    PubMed     Abstract available


  54. DINIZ SN, da Silva CF, de Almeida IT, da Silva Costa FE, et al
    INFbeta treatment affects global DNA methylation in monocytes of patients with multiple sclerosis.
    J Neuroimmunol. 2021;355:577563.
    PubMed     Abstract available


    March 2021
  55. LAZAREVIC M, Djedovic N, Stanisavljevic S, Dimitrijevic M, et al
    Complete Freund's adjuvant-free experimental autoimmune encephalomyelitis in Dark Agouti rats is a valuable tool for multiple sclerosis studies.
    J Neuroimmunol. 2021;354:577547.
    PubMed     Abstract available


  56. GIARRAPUTO J, Giamberardino S, Arvai S, Maichle S, et al
    Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis.
    J Neuroimmunol. 2021;354:577541.
    PubMed     Abstract available


    February 2021
  57. XIANG W, Xie C, Guan Y
    The identification, development and therapeutic potential of IL-10-producing regulatory B cells in multiple sclerosis.
    J Neuroimmunol. 2021;354:577520.
    PubMed     Abstract available


  58. LUCCHINI M, Giuffre GM, Nociti V, Bianco A, et al
    Defining the disease course of TNFalpha blockers-associated Multiple Sclerosis.
    J Neuroimmunol. 2021;353:577525.
    PubMed     Abstract available


  59. UCHIDA N, Mori K, Fujita-Nakata M, Nakanishi M, et al
    Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients.
    J Neuroimmunol. 2021;353:577500.
    PubMed     Abstract available


  60. LI Q, Liu Y, Zeng Y
    Questions about data: Importance of serum amyloid A level in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577516.
    PubMed    


    January 2021
  61. KHADEMI B, Khorrami M, Ayromlou H, Rikhtegar R, et al
    An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577507.
    PubMed     Abstract available


  62. MIMPEN M, Rolf L, Muris AH, Gerlach O, et al
    NK/T cell ratios associate with interleukin-2 receptor alpha chain expression and shedding in multiple sclerosis.
    J Neuroimmunol. 2021;353:577499.
    PubMed     Abstract available


  63. ONMAZ DE, Isik SMT, Abusoglu S, Ekmekci AH, et al
    Serum ADMA levels were positively correlated with EDSS scores in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577497.
    PubMed     Abstract available


  64. NIU Y, Li Y
    The serum alpha-synuclein levels in patients with multiple sclerosis need more evidence.
    J Neuroimmunol. 2021;352:577465.
    PubMed    


  65. ZILIOTTO N, Lamberti N, Manfredini F, Straudi S, et al
    Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.
    J Neuroimmunol. 2021;352:577473.
    PubMed     Abstract available


    December 2020
  66. STASCHEIT F, Li L, Mai K, Baum K, et al
    Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis - A report of two cases.
    J Neuroimmunol. 2020;351:577469.
    PubMed     Abstract available


  67. YOKOTE H, Toru S, Nishida Y, Hattori T, et al
    Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis.
    J Neuroimmunol. 2020;351:577466.
    PubMed     Abstract available


  68. GARCIA-FERNANDEZ FJ, Garcia-Fernandez AE, Nava E, Del Pozo JSG, et al
    A bibliometric evaluation of the top 100 cited natalizumab articles.
    J Neuroimmunol. 2020;349:577379.
    PubMed     Abstract available


    November 2020
  69. BILGE N, Simsek F, Yevgi R, Ceylan M, et al
    Low serum Alpha-SYNUCLEIN and oligomer Alpha-SYNUCLEIN levels in multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577432.
    PubMed     Abstract available


  70. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
    Alterations in peripheral blood monocyte and dendritic cell subset homeostasis in relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577433.
    PubMed     Abstract available


  71. GONCALVES MVM, Brandao WN, Longo C, Peron JPS, et al
    Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
    J Neuroimmunol. 2020;350:577435.
    PubMed     Abstract available


    October 2020
  72. MARTINEZ-LARROSA J, Matute-Blanch C, Montalban X, Comabella M, et al
    Modelling multiple sclerosis using induced pluripotent stem cells.
    J Neuroimmunol. 2020;349:577425.
    PubMed     Abstract available


    September 2020
  73. NEKRASOVA I, Shirshev S
    Estriol in regulation of cell-mediated immune reactions in multiple sclerosis.
    J Neuroimmunol. 2020;349:577421.
    PubMed     Abstract available


  74. HAWKE S, Zinger A, Juillard PG, Holdaway K, et al
    Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    J Neuroimmunol. 2020;349:577392.
    PubMed     Abstract available


    June 2020
  75. NAJJAR E, Staun-Ram E, Volkowich A, Miller A, et al
    Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS.
    J Neuroimmunol. 2020;343:577230.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: